Business Wire

Mavenir’s RCS Mobile Business Messaging Cloud Completes Interconnection between Telefónica, Vodafone, and Deutsche Telekom Germany

Share

Mavenir, the industry’s only end-to-end, cloud-native Network Software Provider and a leader in messaging and Rich Communication Services (RCS) today announced its Mobile Business Messaging Cloud in Europe completed peer-to-peer (P2P) RCS interconnection with the networks of Telefónica (BME:TEF), Vodafone (OTCMKTS: VODPF) and Deutsche Telekom Germany.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200623005331/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

This represents one of the largest RCS carrier interconnections achieved to date, with an estimated addressable market of more than 158 million RCS-upgradeable mobile subscribersi in 13 countries. This includes 3 Telefónica markets, 13 Vodafone markets, and Deutsche Telekom Germany, as well as other carriers.

With three MNOs currently under deployment, covering up to 40 million RCS upgradeable users, Mavenir Mobile Business Messaging Cloud is one of the largest RCS cloud services in the market with interconnection.

These interconnections allow MNOs choosing Mavenir’s Mobile Business Messaging Cloud to eliminate the technical complexities and costs of interconnecting with other MNOs in their regions of operation and lets them focus on commercial terms.

“Interconnecting with these partners required a significant amount of expertise and effort by all parties. Our engineering and operations teams worked very closely with their peers at Vodafone, Telefónica and Deutsche Telekom. It was a team effort, with all parties at the table willing to participate and it shows in the results,” said Guillaume Le Mener, SVP Business Mobility, Mavenir. “This milestone paves the way for accelerated and simplified future MNO onboarding and participation.”

Mavenir’s Mobile Business Messaging Cloud is a Software-as-a-Service (SaaS) RCS Business Messaging (RBM) implementation—operated by Mavenir—that allows MNOs to easily deliver consumer and business RCS messaging services. The cloud solution includes the RCS and IMS Cores, as well as the session border controllers (SBC) and firewalls required for RCS P2P messaging, and the MaaP (Messaging as a Platform) layer to deliver application-to-person (A2P) and person-to-application (P2A) business messaging to users, including chatbot experiences and advanced business messaging services.

Mavenir’s fully compliant with Universal Profile 2.0 RCS solution, supports enhanced mobile messaging features such as open group chat, delivery, is-typing, read notifications, image and file transfer, and audio/video messages for P2P communications. It also supports rich cards and rich card carousels, buttons and suggested responses, among other features, to provide enhanced A2P and P2A business messaging interactions with brands. The solution also leverages Mavenir’s growing Business Messaging Ecosystem, which has close to 70 members, including aggregators, chatbot and business application developers, as well as CPaaS providers.

About Mavenir:

Mavenir is the industry's only end-to-end, cloud-native Network Software Provider focused on accelerating software network transformation and redefining network economics for Communications Service Providers (CSPs). Mavenir offers a comprehensive end-to-end product portfolio across every layer of the network infrastructure stack. From 5G application/service layers to packet core and RAN, Mavenir leads the way in evolved, cloud-native networking solutions enabling innovative and secure experiences for end users. Leveraging innovations in IMS (VoLTE, VoWiFi, Advanced Messaging (RCS), Private Networks as well as vEPC, 5G Core and OpenRAN vRAN, Mavenir accelerates network transformation for more than 250+ CSP customers in over 140 countries, which serve over 50% of the world’s subscribers.

Mavenir embraces disruptive, innovative technology architectures and business models that drive service agility, flexibility, and velocity. With solutions that propel NFV evolution to achieve web-scale economics, Mavenir offers solutions to help CSPs with cost reduction, revenue generation, and revenue protection. www.mavenir.com

Mavenir and the M logo are trademarks owned by Mavenir Systems, Inc.
Copyright © 2020 Mavenir Systems, Inc. All Rights Reserved.

_________
i Mavenir estimation based on Smartphone numbers and Android penetration per country from GSMA data and other sources.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Maryvonne Tubb
Mavenir PR

NA-Loren Guertin
MatterNow

EMEA-Kevin Taylor
GlobalResultsPR

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release

Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release

MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye